Pharma & Biotech
Allergy Therapeutics: Profitable with strong product pipeline
ImmuPharma pushes ahead with drug research efforts
Synairgen to start trials for coronavirus treatment
Only registered members can use this feature.
© Proactive Investors 2019.
Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority. Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.